Literature DB >> 8895517

p53 modulation of anchorage independent growth and experimental metastasis.

M A Nikiforov1, K Hagen, V S Ossovskaya, T M Connor, S W Lowe, G I Deichman, A V Gudkov.   

Abstract

Death in circulation is one of the natural barriers preventing dissemination of tumor cells and formation of metastases. One of the negative factors acting in circulation is the loss of cell contact with natural substrate which can be imitated in vitro by the incubation of cells in suspension or in semi-solid media. Normal mouse fibroblasts (MEFs) stay viable in suspension and undergo p53-independent G1 growth arrest. Transformation with Ela and ras oncogenes leads to the abrogation of this arrest and to the p53-dependent apoptosis occurring in G1 phase of the cell cycle. Suppression of apoptosis by p53 gene knock-out, transduction of dominant negative p53 mutant or bcl-2 prevents death in suspension and greatly induces frequency of colony formation in semi-solid media. The ability of cells to undergo apoptosis does not correlate with their tumorigenicity in nude mice but does correlate with their ability to survive in lungs of intravenously injected mice and to form experimental metastases. We suggest that abrogation of a p53-mediated apoptosis facilitates experimental metastasis by promoting survival of tumor cells in circulation.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8895517

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  22 in total

1.  Alternatively spliced products CC3 and TC3 have opposing effects on apoptosis.

Authors:  S Whitman; X Wang; R Shalaby; E Shtivelman
Journal:  Mol Cell Biol       Date:  2000-01       Impact factor: 4.272

Review 2.  Apoptosis and myofibroblasts in the pathogenesis of systemic sclerosis.

Authors:  Eugene Kissin; Joseph H Korn
Journal:  Curr Rheumatol Rep       Date:  2002-04       Impact factor: 4.592

3.  Transgenic mice with p53-responsive lacZ: p53 activity varies dramatically during normal development and determines radiation and drug sensitivity in vivo.

Authors:  E A Komarova; M V Chernov; R Franks; K Wang; G Armin; C R Zelnick; D M Chin; S S Bacus; G R Stark; A V Gudkov
Journal:  EMBO J       Date:  1997-03-17       Impact factor: 11.598

4.  Direct inhibition of retinoblastoma phosphorylation by nimbolide causes cell-cycle arrest and suppresses glioblastoma growth.

Authors:  Swagata Karkare; Rishi Raj Chhipa; Jane Anderson; Xiaona Liu; Heather Henry; Anjelika Gasilina; Nicholas Nassar; Jayeeta Ghosh; Jason P Clark; Ashish Kumar; Giovanni M Pauletti; Pradip K Ghosh; Biplab Dasgupta
Journal:  Clin Cancer Res       Date:  2013-10-29       Impact factor: 12.531

5.  Immunophenotyping of human HT29 colon cancer cell primary tumours and their metastases in severe combined immunodeficient mice.

Authors:  B S Mitchell; H P Horny; U Schumacher
Journal:  Histochem J       Date:  1997-05

6.  miR-125b Is an adhesion-regulated microRNA that protects mesenchymal stem cells from anoikis.

Authors:  Xiang Yu; Daniel M Cohen; Christopher S Chen
Journal:  Stem Cells       Date:  2012-05       Impact factor: 6.277

7.  Induction of cell cycle progression and acceleration of apoptosis are two separable functions of c-Myc: transrepression correlates with acceleration of apoptosis.

Authors:  S D Conzen; K Gottlob; E S Kandel; P Khanduri; A J Wagner; M O'Leary; N Hay
Journal:  Mol Cell Biol       Date:  2000-08       Impact factor: 4.272

8.  Detyrosinated microtubule protrusions in suspended mammary epithelial cells promote reattachment.

Authors:  Rebecca A Whipple; Agnes M Cheung; Stuart S Martin
Journal:  Exp Cell Res       Date:  2007-02-07       Impact factor: 3.905

Review 9.  Contribution of p53 to metastasis.

Authors:  Emily Powell; David Piwnica-Worms; Helen Piwnica-Worms
Journal:  Cancer Discov       Date:  2014-03-21       Impact factor: 39.397

Review 10.  Versatile functions of p53 protein in multicellular organisms.

Authors:  P M Chumakov
Journal:  Biochemistry (Mosc)       Date:  2007-12       Impact factor: 2.487

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.